Beta Footprint » phase

Neurologix Completes All Surgical Procedures In Its Clinical Trial For Parkinson’s Disease

admin — Fri, 11 Dec 2009 04:00:00 +0000

Neurologix, Inc.

Initiation Of CYT107 Study In HBV Expands Company’s Hepatitis Investigations, Which Include Three Ongoing Studies In Hepatitis C (HCV)

Master — Tue, 08 Dec 2009 13:00:00 +0000

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in combination with standard antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B-infected (HBV) patients…

Biogen Idec’s Oral Compound BG-12 Achieves Development Milestones In MS And RA

admin — Tue, 08 Dec 2009 13:00:00 +0000

Biogen Idec (NASDAQ: BIIB) today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA). In recent months, the last patient was enrolled in the CONFIRM trial, the second of two Phase III trials designed to evaluate the efficacy and safety of BG-12 as a monotherapy in patients with relapsing-remitting multiple sclerosis (RRMS)…

PharmAthene Presents Phase I Clinical Trial Results And New Therapeutic Animal Model Data For Protexia(R)

Master — Tue, 08 Dec 2009 08:00:00 +0000

PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced Phase I clinical trial results for Protexia®, a pegylated recombinant version of human butyrylcholinesterase (rBChE), which has been shown to be effective in animal models in preventing toxicity from exposure to chemical nerve agents…

Carfilzomib Demonstrates Encouraging Response Rates In Patients With Relapsed And/or Refractory Multiple Myeloma In An Ongoing Phase 2 Study

Master — Tue, 08 Dec 2009 08:00:00 +0000

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced results from an ongoing Phase 2 study, known as the 004 study, of the company’s lead proteasome inhibitor, carfilzomib.

Aradigm Doses First Patient In Long-Term Phase 2 Study Of A Novel Inhaled Ciprofloxacin Formulation For The Management Of Respiratory Infections

Master — Wed, 18 Nov 2009 08:00:00 +0000

Aradigm Corporation (OTCBB:ARDM) (the “Company”) announced that the first patient was dosed in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis. The randomized, double-blind, placebo-controlled trial will be conducted in Australia and New Zealand.

Aradigm Doses First Patient In Long-Term Phase 2 Study Of A Novel Inhaled Ciprofloxacin Formulation For The Management Of Respiratory Infections

admin — Wed, 18 Nov 2009 08:00:00 +0000

Winston Laboratories, Inc. Announces Positive Top-line Results Of Phase II Clinical Trial Of Civamide Patch

admin — Wed, 18 Nov 2009 08:00:00 +0000

Winston Laboratories, Inc.

Phase 1/2 Results For Aldagen’s ALD-301 Critical Limb Ischemia Clinical Study Presented At AHA

admin — Tue, 17 Nov 2009 08:00:00 +0000

Aldagen, Inc. announced that researchers presented results from its multicenter Phase 1/2 clinical trial of ALD-301, a cell therapy being developed as a treatment for advanced critical limb ischemia (CLI), the most severe form of peripheral arterial disease (PAD).

Phase 1/2 Results For Aldagen’s ALD-301 Critical Limb Ischemia Clinical Study Presented At AHA

admin — Tue, 17 Nov 2009 08:00:00 +0000

The Medicines Company’s Full Analysis Of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patient Outcomes Following PCI

admin — Mon, 16 Nov 2009 11:00:00 +0000

The Medicines Company (NASDAQ: MDCO) announced the data from 13,941 patients treated in the discontinued CHAMPION Phase III program of cangrelor.

Addex ADX10059 Monotherapy Is Effective On GERD Symptoms In Phase IIb Clinical Trial

Master — Mon, 16 Nov 2009 11:00:00 +0000

Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced that it achieved statistically significant efficacy on the primary endpoint, increasing the number of symptom free days in the Phase IIb trial of ADX10059 as a monotherapy in patients with gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms.

Abbott To Acquire Novel Investigational Biologic To Treat Chronic Pain

Master — Sun, 15 Nov 2009 08:00:00 +0000

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV’s PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company’s pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.

Esperion Therapeutics Initiates Phase I Clinical Study For ETC-1002

Master — Sat, 14 Nov 2009 09:00:00 +0000

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, announced that the company has initiated a Phase I clinical study for ETC-1002, the company’s novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.

Theratechnologies Presents Combined Phase 3 Clinical Results At European AIDS Conference

Master — Thu, 12 Nov 2009 11:00:00 +0000

Theratechnologies (TSX:TH) announced that results from a pooled analysis from both its Phase 3 clinical trials evaluating tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy were presented as a poster (Poster number: #BPD2/1) at the 12th European AIDS Conference/EACS in Cologne, Germany.

Tokai Pharmaceuticals Initiates ARMOR Clinical Development Program For TOK-001; First Ever Multi-Target Investigational Drug For Prostate Cancer

admin — Thu, 12 Nov 2009 08:00:00 +0000

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC).

ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data At The 2009 Annual Meeting Of The American College Of Allergy, Asthma & Immunology…

admin — Tue, 10 Nov 2009 09:00:00 +0000

ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced additional results from the Company’s Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies.

ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data At The 2009 Annual Meeting Of The American College Of Allergy, Asthma & Immunology…

admin — Tue, 10 Nov 2009 09:00:00 +0000

ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced additional results from the Company’s Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies. These results were presented in poster sessions at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Miami Beach, FL

Cytokinetics Announces Advancement Of CK-2017357 In Phase I Clinical Trials

Master — Tue, 10 Nov 2009 09:00:00 +0000

Cytokinetics, Incorporated (NASDAQ: CYTK) announced the initiation of a double-blind, randomized, placebo-controlled, multiple-dose Phase I clinical trial to investigate the pharmacokinetic profile of CK-2017357.

Cytokinetics Announces Advancement Of CK-2017357 In Phase I Clinical Trials

Master — Tue, 10 Nov 2009 09:00:00 +0000

Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results At CTOS Annual Meeting

admin — Sat, 07 Nov 2009 09:00:00 +0000

Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) (”Oncolytics” or the “Company”) announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th.

Novexel Starts Phase II Clinical Trial With NXL103 In Adults With Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

Master — Sat, 07 Nov 2009 09:00:00 +0000

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI).

ERYtech Pharma Starts Its Pivotal Clinical Trial For GRASPA(R) In Acute Lymphoblastic Leukaemia

admin — Sat, 07 Nov 2009 05:00:00 +0000

ERYtech Pharma announces the start of its pivotal clinical trial for GRASPA®, its lead product in Acute Lymphoblastic Leukaemia. This phase III trial has begun in France and will be enlarged to a European scale

Amgen Announces Overall Survival Results For Vectibix(R) In First-Line Metastatic Colorectal Cancer

admin — Fri, 06 Nov 2009 10:00:00 +0000

Amgen (Nasdaq: AMGN) announced that the Phase 3 PRIME “203″ trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.

Affymax And Takeda Announce Hematide™ Publication In The New England Journal Of Medicine

admin — Thu, 05 Nov 2009 20:00:00 +0000

Affymax, Inc.